Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients : Modelling the combined effects of HIV and heart disease

Clinical Drug Investigation

Volumn 27, Issue 1, 2007, Pages 67-74

  Simpson, Kit N ^a,c   Luo, Michelle P ^b   Chumney, Elinor C ^a   King, Martin S ^b   Brun, Scott ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b ABBOTT LABORATORIES   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; DATA BASE; FEMALE; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SURVIVAL; TREATMENT DURATION;

EID: 33846093627     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727010-00006     Document Type: Article

References (14)

1. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. DHHS Panel on Antiretroviral Guidelines, October 10, 2006. Office of AIDS Research Advisory Council [online]. Available from URL: http://AID-Sinfo.nih.gov [Accessed 2006 Nov 7]
2. FDA Center for Drug Evaluation & Research. Application 21-567 Statistical Review(s) 2002 [online]. Available from URL: http://www.fda.gov/ cder/foi/nda/2003/21-567_Reyataz_Statr.pdf [Accessed 2006 Nov 7]
3. Drummond M, Schulpher M. Common methodological flaws in economic evaluations. Med Care 2005; 43 (7 Suppl.): II5-II14
4. Simpson KN, Luo MP, Chumney EG, et al. Cost effectiveness of using lopinavir/ritonavir vs nelfinavir as the first highly active antiretroviral regimen for HIV infection. HIV Clinical Trials 2004; 5: 294-304
5. Wong ND, Wilson PW, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med 1991; 11 (5): 687-93
6. Ghani AC, de Wolf F, Ferguson NM, et al. Surrogate markers for disease progression in treated HIV infection. J Acquir Immune Defic Syndr 2001; 28 (3): 226-31
7. Ghani AC, Henley WE, Donnelly CA, et al. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases. AIDS 2001; 15 (9): 1133-42
8. Gathe J, Podzamczer D, Johnson M, et al. Once-daily vs twice-daily lopinavir in antiretroviral-naive patients: 48-week results. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA 2004 Feb, Poster #570
9. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir vs. nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346 (26): 2039-46
10. Simpson KN. Unpublished Medicaid costs data for South Carolina for years 2001 and 2002 inflated by the Medical Care CPI to 2004 values
11. Price Probe™ 2004 [online]. Available from URL: http://www.firstdatabank.com/reference_products/price_probe [Acessed 2006 Dec 1]
12. Dolan P. Modeling valuations for EuroQoL health states. Med Care 1998; 35: 1095-108
13. Castiel D, Herve C, Gaillard M, et al. Cost-utility analysis of early thrombolytic therapy. Pharmacoeconomics 1992; 1 (6): 438-42
14. d'Arminio A, Sabin CA, Phillips AN, et al. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004; 18 (13): 1811-7